# Will Stratton

> Will Stratton is the Chief Business Officer and Head of Strategy and Planning at Autobahn Therapeutics, a San Diego biotech building brain-targeting small molecules for neuropsychiatric and neuroimmunologic disorders. A Yale chemist turned Wharton-trained dealmaker, he helped steer the company's oversubscribed $100 million Series C in 2024 and runs the corporate strategy behind a pipeline led by ABX-002, a thyroid hormone receptor beta agonist for depression.

- **Role:** Chief Business Officer and Head of Strategy and Planning at Autobahn Therapeutics
- **Organizations:** Autobahn Therapeutics, Avelas Biosciences, Rakuten Medical, NAVICAN (now Intermountain Precision Genomics)
- **Nationality:** American
- **Education:** MBA, Healthcare Management and Entrepreneurial Management, The Wharton School, University of Pennsylvania, B.S. in Chemistry, Yale University
- **Known for:** Helped advance Autobahn Therapeutics' oversubscribed $100 million Series C financing in July 2024, Holds an MBA from the Wharton School with majors in healthcare management and entrepreneurial management, Holds a B.S. in Chemistry from Yale University, bridging deep science and business strategy

## Career timeline

- **Early career** — Management consulting, advising life sciences clients on business development and commercial strategy
- **Pre-2017** — Business development and strategic planning roles at NAVICAN (now Intermountain Precision Genomics)
- **2015-2017** — Earned MBA at the Wharton School, University of Pennsylvania
- **Mid-career** — Global business and corporate development at Rakuten Medical, focused on early-stage R&D dealmaking
- **Later** — Vice President of Business Development at Avelas Biosciences, leading corporate development, financing, strategy, and investor relations
- **2024** — As a senior business leader at Autobahn Therapeutics, supported the oversubscribed $100M Series C financing
- **2026** — Chief Business Officer and Head of Strategy and Planning at Autobahn Therapeutics

## Achievements

- Helped advance Autobahn Therapeutics' oversubscribed $100 million Series C financing in July 2024
- Holds an MBA from the Wharton School with majors in healthcare management and entrepreneurial management
- Holds a B.S. in Chemistry from Yale University, bridging deep science and business strategy
- Led business development, financing, and investor relations as VP at Avelas Biosciences

## Latest updates

- **2026-04** — Autobahn Therapeutics announced participation in the 25th Annual Needham Virtual Healthcare Conference
- **2024-07** — Autobahn completed an oversubscribed $100M Series C to advance ABX-002 into Phase 2

## Links

- Website: https://autobahntx.com
- LinkedIn: https://www.linkedin.com/in/williampstratton

---

Profile page: https://yespress.io/will-stratton
Published by YesPress — https://yespress.io
Last updated: 2026-06-04